Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    


Study Underscores Importance of Personalized Medicine in Kidney Cancer


 

A new study sheds light on how molecular subsets within the tumors of kidney cancer patients determine treatment outcomes and underscores the importance of personalized medicine in making therapy decisions.

The study published Thursday, Nov. 5, in Cancer Cell is a comprehensive molecular analysis of 823 tumors donated by patients with advanced renal cell carcinoma (RCC) who were either treated with the immunotherapies atezolizumab and bevacizumab in combination or the targeted therapy sunitinib.

Researchers validated for the first time the prognostic and predictive capability of transcriptional signatures and described the distinct molecular subtypes that associate with different outcomes to these cancer treatments. They also identified additional molecular targets for future drug development

"These data were a massive undertaking and are the most comprehensive analysis of RCC tumors from a phase 3 trial to date. They further refine the known angiogenic and inflammatory biology of RCC, but also shed light on proliferative and metabolic pathways that are relevant." said Brian Rini, MD, Ingram Professor of Cancer Research and chief of Clinical Trials at Vanderbilt-Ingram Cancer Center (VICC), the study's senior author

Approximately 25% of renal cell carcinoma patients have metastatic cancer at the time of diagnosis, and studies of tumors taken from those patients indicate that 20% of those specimens include a sarcomatoid component. Patients with metastasized cancer whose tumors that include a sarcomatoid component have poor clinical prognosis. Of the 823 tumors studied, 134 had sarcomatoid features.

The researchers identified seven tumor subsets for renal cell carcinoma, including those with sarcomatoid features. The seven molecular subsets are identified in an illustration on the first page of the study along with which treatment had better efficacy. The seven subtypes are Angiogenic/Stromal, Angiogenic, Complement/W-oxidation, T-effector/Proliferative, Stromal/Proliferative and snoRNA.

These data can be used to tailor a biomarker-based approach to select specific therapies for specific patients. This will require further validation of these clusters in prospective trials.

The study highlights the importance of personalized medicine and molecular tumor boards in guiding treatment decisions. Molecular tumor boards are composed of highly specialized cancer experts, including genomics specialists. VICC has a molecular tumor board composed of medical oncologists, molecular pathologists, lab scientists, genetics counselors and bioinformatics experts.

 
Share:

Related Articles:


Recent Articles

Hot spots identified for colorectal cancer mortality rates among young women

Read More

ONcology Rounds

Read More

Minority Report

All cancers are not created equally. Recent Vanderbilt research show stomach, lung and appendiceal cancers are on the rise and detected later among certain ethnic groups.

Read More

Rounding on Addiction

Read More

Women and Addiction

Prenatal addiction services needed to bridge the gap in addiction, obstetrics

Read More

State of Recovery

Efforts are underway by TDMHSAS leadership to reach more Tennesseans suffering with addiction through education and recovery initiatives.

Read More

AMA Backs Policy Proposals to Cover More of the Uninsured

CHICAGO -- The American Medical Association (AMA) House of Delegates adopted principles today supporting public policy approaches that have the potential to expand insurance coverage to millions of the uninsured, including those who have lost their coverage during the COVID-19 pandemic.

Read More

Statins to be Studied for Prevention of Dementia, Disability, and Heart Disease

Vanderbilt University Medical Center (VUMC) researchers are enrolling adults age 75 and over to study whether taking atorvastatin, a drug commonly used to lower cholesterol, also called Lipitor®, can help maintain health by preventing dementia, disability, and heart disease.

Read More

Addressing Opioid Usage in the Hospital Setting

Opioid misuse often traces its roots to medically valid pain management intervention. Increased awareness of addiction has led providers to look for effective alternatives. In the hospital setting, recent studies find Caldolor® might be one such option.

Read More

Nashville Health Care Council: 25 Years Old & Growing

This year marks the 25th anniversary of the Nashville Health Care Council, an organization that was founded by the local health care community with the purpose of establishing Nashville as the nation's health care capital.

Read More

Email Print
 
 

 

 


Tags:
oncology
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: